US20040072880A1 - Cycloalkyl inhibitors of potassium channel function - Google Patents

Cycloalkyl inhibitors of potassium channel function Download PDF

Info

Publication number
US20040072880A1
US20040072880A1 US10/356,158 US35615803A US2004072880A1 US 20040072880 A1 US20040072880 A1 US 20040072880A1 US 35615803 A US35615803 A US 35615803A US 2004072880 A1 US2004072880 A1 US 2004072880A1
Authority
US
United States
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclo
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/356,158
Other languages
English (en)
Inventor
John Lloyd
Yoon Jeon
Heather Finlay
Lin Yan
Michael Gross
Serge Beaudoin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Icagen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/356,158 priority Critical patent/US20040072880A1/en
Assigned to ICAGEN, INC. reassignment ICAGEN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEAUDOIN, SERGE, GROSS, MICHAEL F.
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YAN, LIN, FINLAY, HEATHER, JEON, YOON T., LLOYD, JOHN
Publication of US20040072880A1 publication Critical patent/US20040072880A1/en
Priority to US10/997,734 priority patent/US7202253B2/en
Priority to US11/670,482 priority patent/US20070142333A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/55—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/66—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing five-membered rings

Definitions

  • the present invention provides for cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, more especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ) and to pharmaceutical compositions containing such compounds.
  • the present invention further provides for methods of using such compounds in the treatment of arrhythmia, I Kur -associated disorders, and other disorders mediated by ion channel function.
  • potassium channels have turned out to be the most diverse family of ion channels discovered to date. They modulate a number of cellular events such as muscle contraction, neuro-endocrine secretion, frequency and duration of action potentials, electrolyte homeostatis, and resting membrane potential.
  • Potassium channels are expressed in eukaryotic and procaryotic cells and are elements in the control of electrical and non-electrical cellular functions. Potassium channels have been classified according to their biophysical and pharmacological characteristics. Subclasses of these channels have been named based on amino acid sequence and functional properties. Salient among these are the voltage dependent potassium channels, for example voltage gated potassium channels (e.g., K v 1, K v 2, K v 3, K v 4).
  • voltage gated potassium channels e.g., K v 1, K v 2, K v 3, K v 4
  • K v 1 class of potassium channels is further subdivided depending on the molecular sequence of the channel, for example K v 1.1, K v 1.2, K v 1.3, K v 1.4, K v 1.5, K v 1.6, and K v 1.7.
  • Functional voltage-gated K + channels can exist as multimeric structures formed by the association of either identical or dissimilar subunits. This phenomena is thought to account for the wide diversity of K + channels. However, subunit compositions of native K + channels and the physiologic role that particular channels play are, in most cases, still unclear.
  • the K v 1.3 voltage-gated potassium channel is found in neurons, blood cells, osteoclasts and T-lymphocytes.
  • the Chandy and Cahalan laboratories proposed a hypothesis that blocking the K v 1.3 channel would elicit an immunosuppressant response. (Chandy et al., J. Exp. Med. 160, 369, 1984; Decoursey et al., Nature, 307, 465, 1984).
  • the K + channel blockers employed in their studies were non-selective.
  • a peptide found in scorpion venom no specific inhibitor of the K v 1.3 channel existed to test this hypothesis.
  • a laboratory Price et al., Proc.
  • Immunoregulatory abnormalities have been shown to exist in a wide variety of autoimmune and chronic inflammatory diseases, including systemic lupus erythematosis, chronic rheumatoid arthritis, type I and II diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy and asthma.
  • autoimmune or a rejection process tissue destruction caused by inflammatory cells and the mediators they release.
  • Anti-inflammatory agents such as NSAID's act principally by blocking the effect or secretion of these mediators but do nothing to modify the immunologic basis of the disease.
  • cytotoxic agents such as cyclophosphamide, act in such a nonspecific fashion that both the normal and autoimmune responses are shut off. Indeed, patients treated with such nonspecific immunosuppressive agents are as likely to succumb from infection as they are from their autoimmune disease.
  • Cyclosporin A which was approved by the US FDA in 1983 is currently the leading drug used to prevent rejection of transplanted organs.
  • FK-506 Prograf
  • CsA and FK-506 act by inhibiting the body's immune system from mobilizing its vast arsenal of natural protecting agents to reject the transplant's foreign protein.
  • CsA was approved by the US FDA for the treatment of severe psoriasis and has been approved by European regulatory agencies for the treatment of atopic dermatitis. Though they are effective in fighting transplant rejection, CsA and FK-506 are known to cause several undesirable side effects including nephrotoxicity, neurotoxicity, and gastrointestinal discomfort. Therefore, a selective immunosuppressant without these side effects still remains to be developed. Potassium channel inhibitors promise to be the solution to this problem.
  • Atrial fibrillation (AF) and atrial flutter are the most common cardiac arrhythmias in clinical practice and are likely to increase in prevalence with the aging of the population.
  • AF affects more than 1 million Americans annually, represents over 5% of all admissions for cardiovascular diseases and causes more than 80,000 strokes each year in the United States.
  • AF is rarely a lethal arrhythmia, it is responsible for substantial morbidity and can lead to complications such as the development of congestive heart failure or thromboembolism.
  • Class I and Class III antiarrhythmic drugs reduce the rate of recurrence of AF, but are of limited use because of a variety of potentially adverse effects including ventricular proarrhythmia. Because current therapy is inadequate and fraught with side effects, there is a clear need to develop new therapeutic approaches.
  • Antiarrhythmic agents of Class III are drugs that cause a selective prolongation of the duration of the action potential without significant cardiac depression. Available drugs in this class are limited in number. Examples such as sotalol and amiodarone have been shown to possess interesting Class III properties (Singh B. N., Vaughan Williams E. M. “A Third Class of Anti-Arrhythmic Action: Effects On Atrial And Ventricular Intracellular Potentials And Other Pharmacological Actions On Cardiac Muscle, of MJ 1999 and AH 3747” Br. J. Pharmacol 1970; 39:675-689. and Singh B. N., Vaughan Williams E.
  • Class III agents increase myocardial refractoriness via a prolongation of cardiac action potential duration.
  • prolongation of the cardiac action potential can be achieved by enhancing inward currents (i.e. Na + or Ca 2+ currents; hereinafter I Na and I Ca , respectively) or by reducing outward repolarizing potassium (K + ) currents.
  • the delayed rectifier (I K ) K + current is the main outward current involved in the overall repolarization process during the action potential plateau, whereas the transient outward (I to ) and inward rectifier (I KI ) K + currents are responsible for the rapid initial and terminal phases of repolarization, respectively.
  • I K consists of two pharmacologically and kinetically distinct K + current subtypes, I Kr (rapidly activating and deactivating) and I Ks (slowly activating and deactivating) (Sanguinetti and Jurkiewicz, Two Components Of Cardiac Delayed Rectifier K + Current: Differential Sensitivity To Block By Class III Antiarrhythmic Agents, J Gen Physiol 1990, 96:195-215).
  • Class III antiarrhythmic agents currently in development including d-sotalol, dofetilide (UK-68,798), almokalant (H234/09), E-4031 and methanesulfonamide-N-[1′-6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4′-piperidin]-6yl]monochloride, predominantly, if not exclusively, block I Kr .
  • amiodarone is a blocker of I Ks (Balser J. R. Bennett, P. B., Hondeghem, L. M. and Roden, D. M.
  • Reentrant excitation has been shown to be a prominent mechanism underlying supraventricular arrhythmias in man.
  • Reentrant excitation requires a critical balance between slow conduction velocity and sufficiently brief refractory periods to allow for the initiation and maintenance of multiple reentry circuits to coexist simultaneously and sustain AF.
  • Increasing myocardial refractoriness by prolonging action potential duration (APD) prevents and/or terminates reentrant arrhythmias.
  • Most selective Class III antiarrhythmic agents currently in development, such as d-sotalol and dofetilide predominantly, if not exclusively, block I kr , the rapidly activating component of I K found both in the human atrium and ventricle.
  • I kr blockers increase APD and refractoriness both in atria and ventricle without affecting conduction per se, theoretically they represent potential useful agents for the treatment of arrhythmias like AF. These agents have a liability in that they have an enhanced risk of proarrhythmia at slow heart rates. For example, torsades de points has been observed when these compounds are utilized (Roden, D. M. “Current Status of Class III Antiarrhythmic Drug Therapy”, Am J. Cardiol, 1993; 72:44B-49B). This exaggerated effect at slow heart rates has been termed “reverse frequency-dependence”, and is in contrast to frequency-independent or frequency-dependent actions (Hondeghem, L. M. “Development of Class III Antiarrhythmic Agents”. J.Cadiovasc.Cardiol. 20 (Suppl.2):S17-S22).
  • the slowly activating component of the delayed rectifier potentially overcomes some of the limitations of I kr blockers associated with ventricular arrhythmias. Because of its slow activation kinetics however, the role of I ks in atrial repolarization may be limited due to the relatively short APD of the atrium. Consequently, although I ks blockers may provide distinct advantage in the case of ventricular arrhythmias, their ability to affect SVT is considered to be minimal.
  • I kur The ultra-rapidly activating delayed rectifier K + current (I kur ) is believed to represent the native counterpart to a cloned potassium channel designated Kv1.5 and, while present in human atrium, it appears to be absent in human ventricle. Furthermore, because of its rapidity of activation and limited slow inactivation, I kur is believed to contribute significantly to repolarization in human atrium.
  • antiarrythmic agents of Class I according to the classification scheme of Vaughan-Williams (“Classification Of Antiarrhythmic Drugs: In: Cardiac Arrhythmias, edited by: E. Sandoe, E. Flensted-Jensen, K. Olesen; Sweden, Astra, Sodertalje, pp449-472, 1981) which cause a selective inhibition of the maximum velocity of the upstroke of the action potential ( max ) are inadequate for preventing ventricular fibrillation.
  • Beta-adrenoceptor blockers and calcium antagonists which belong to Class II and IV, respectively, have a defect in that their effects are either limited to a certain type of arrhythmia or are contraindicated because of their cardiac depressant properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class I.
  • the present invention provides cycloalkyl compounds of the following formula I, including enantiomers, diastereomers, and salts thereof, useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, more especially inhibitors of K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current, I Kur ) for the treatment of disorders such as arrhythmia and I Kur -associated disorders:
  • the dashed line represents an optional double bond, provided that R 1a is absent when a double bond is present;
  • m and p are independently 0, 1, 2 or 3;
  • R 1 is
  • R 1a is H or R X ;
  • R 1 and R 1a together form oxo
  • R 1 and R 1a together with the carbon atom to which they are attached combine to form an optionally substituted spiro-fused heterocyclo group
  • R 1 and R 1a together combine to form a group
  • R 2 is heteroaryl, (heteroaryl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl or cycloalkyl, any of which may be optionally independently substituted with one or more groups T 1 , T 2 or T 3 ;
  • J is a bond, C 1-4 alkylene optionally independently substituted with one or more groups T 1a , T 2a or T 3a , or C 1-4 alkenylene optionally independently substituted with one or more groups T 1a , T 2a or T 3a ;
  • R 3 is
  • R 4 is alkyl, haloalkyl, alkenyl, cycloalkyl, heterocyclo, aryl, or heteroaryl any of which may be optionally independently substituted with one or more groups T 1b , T 2b or T 3b ;
  • R 4a is R 4 or OR 4 ;
  • R 5 is —NR 6a R 7a , or heteroaryl, (heteroaryl)alkyl, aryl, (aryl)alkyl, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl or alkynyl any of which may be optionally independently substituted with one or more groups T 1c , T 2c or T 3c ;
  • R 6 , R 6a , R 7 , R 8 , R 8a , R 8a1 , R 8a2 , R 8a3 , R 8a4 , R 8a5 and R 9 are independently H, alkyl, hydroxy, alkoxy, aryloxy, heterocyclooxy, heteroaryloxy, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, (heterocyclooxy)alkyl, (heteroaryloxy)alkyl, (cyano)alkyl, (alkenyl)alkyl, (alkynyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, heterocyclo, (heterocyclo)alkyl, —C(O)R, —CO 2 R , —C(O)—NR 12 R 13 , or
  • R 6 and R 7 , or R 6a and R 7a together with the nitrogen atom to which they are attached may combine to form a saturated or unsaturated 4 to 8 membered ring (either cycloalkyl or heterocylco) optionally independently substituted with one or more groups T 1d , T 2d or T 3d ;
  • R 6 or R 7 may combine with one of R 8 , R 8a or R 9 to form a saturated or unsaturated 5 to 8 membered ring (either cycloalkyl or heterocylco) optionally independently substituted with one or more groups T 1d , T 2d or T 3d .
  • R 6a or R 7a may combine with R 8a1 to form a saturated or unsaturated 5 to 8 membered ring (either cycloalkyl or heterocylco) optionally independently substituted with one or more groups T 1d , T 2d or T 3d
  • R 8b is independently H, alkyl, aryl, cyano, nitro, acyl or —SO 2 (alkyl);
  • R 8c is independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, amino or alkoxy;
  • R 8d is R 4 , COR 4 , CO 2 R 4 , SO 2 R 4 , CONR 6 R 7 , or SO 2 —NR 6 R 7 ;
  • R 10 R 10a , R 11 and R 11a are independently H, alkyl, aryl, (aryl)alkyl, alkoxy, (alkoxy)alkyl, halo, hydroxy, (hydroxy)alkyl, amino, amido, heteroaryl, (heteroaryl)alkyl, heterocyclo, (heterocyclo)alkyl, sulfonamido, cycloalkyl, (cycloalkyl)alkyl, or cyano any of which may be optionally independently substituted on available atoms (as allowed by valence) with one or more groups T 1e , T 2e or T 3e ;
  • R 10 and R 10a , or R 11 and R 11a may combine to form oxo;
  • R 10a may combine with R 11a to form a bond
  • R 10 may combine with R 9 to form a saturated or unsaturated ring
  • R 12 and R 13 are independently H, alkyl, hydroxy, alkoxy, aryloxy, heterocyclooxy, heteroaryloxy, (hydroxy)alkyl, (alkoxy)alkyl, (aryloxy)alkyl, (heterocylooxy)alkyl, (heteroaryloxy)alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl, heterocyclo, or (heterocyclo)alkyl any of which may be optionally independently substituted with one or more groups T 1f , T 2f or T 3f
  • R 12 and R 13 together with the nitrogen atom to which they are attached may combine to form a saturated or unsaturated ring (either cycloalkyl or heterocylco) which may be optionally independently substituted with one or more groups T 1f , T 2f or T 3f ;
  • W is ⁇ NR 8a2 , ⁇ N—CO 2 R 8a2 , ⁇ N—COR 8a2 , ⁇ N—CN, or ⁇ N—SO 2 R 8a2 ;
  • Z, Z 1 and Z 2 are independently ⁇ O, ⁇ S, ⁇ NR 8a4 or ⁇ N—CN;
  • R 14 is independently
  • R Y is an optional oxo substituent attached to any available ring carbon atom
  • X 1 is O, S, NR 8a5 or CH 2 ;
  • X 2 is NR 8a5 or CH 2 ;
  • R X is one or more optional substituents, attached to any available ring carbon atom, independently selected from T 1g , T 2g or T 3g ;
  • T 1-1g , T 2-2g , and T 3-3g are each independently
  • alkyl (hydroxy)alkyl, (alkoxy)alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocylco)alkyl, heteroaryl, or (heteroaryl)alkyl;
  • T 4 and T 5 are each independently
  • (1) are each independently hydrogen or a group provided in the definition of T 6 , or
  • T 7 and T 8 may together be alkylene or alkenylene, completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T 1-1g , T 2-2g and T 3-3g , or
  • T 7 or T 8 together with T 9 , may be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more groups listed in the description of T 1-1g , T 2-2g and T 3-3g , or
  • T 7 and T 8 or T 9 and T 10 together with the nitrogen atom to which they are attached may combine to form a group —N ⁇ CT 13 T 14 where T 13 and T 14 are each independently H or a group provided in the definition of T 6 ; and
  • T 11 and T 13 are each independently
  • the present invention provides novel methods for the prevention and treatment of arrhythmia and I Kur -associated disorders employing one or more compounds of the formula I, enantiomers, diastereomers or pharmaceutically acceptable salts thereof.
  • the present invention provides a novel method for the selective prevention and treatment of supraventricular arrhythmias.
  • Preferred compounds within the scope of formula I include compounds of formula I a , I b and I c :
  • Preferred compounds within the scope of formula I include compounds and salts thereof wherein one or more, and especially all of R 1 , R 1a , R 2 , J and R 3 are selected from the following definitions:
  • R 1 is hydrogen, hydroxy, —NR 6 R 7 , —O—C(O)—NR 6 R 7 , —O—C(O)—R 4 , —N(R 8 )—SO 2 —NR 6 R 7 , —N(R 8 )—C(Z)-N(R 8a )—SO 2 —R 4 , —N(R 8 )—C(Z)-N(R 8a )—SO 2 —OH, —SO 2 —R 8c , —N(R 8 )—C(W)—NR 6 R 7 , or a group
  • R 1a is H, or R 1a and R 1 combine from oxo or an optionally substituted spiro-fused heterocyclo group;
  • R 2 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl (especially phenyl or napthyl), optionally substituted (aryl)alkyl (especially benzyl), or optionally substituted heteroaryl (especially thienyl, benzothienyl, pyridinyl or isoxazolyl);
  • J is a bond, optionally substituted C 1-4 alkylene (especially methylene) or optionally substituted C 1-4 alkenylene (especially ethenylene);
  • R 3 is —R, —OR 5 , —C(Z 1 )-R 5 , —C(Z)-O—R 5 , —O—C(Z 1 )-R 5 , —N(R 8a1 )—C(Z 1 )-R 5 , —N(R 8a1 )—C(Z 1 )-O—R 5 , or —N(R 8a1 )—SO 2 —R 5 ;
  • R 5 is optionally substituted aryl, optionally substituted (aryl)alkyl, optionally substituted heteroaryl, optionally substituted (heteroaryl)alkyl, optionally substituted heterocylco, optionally substituted (heterocylco)alkyl, optionally subsituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, —NR 6a R 7a or a group,
  • R 6 , R 6a , R 7 and R 7a are independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted (aryl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted (heterocylco)alkyl, optionally substituted alkyl, or COR 12 ;
  • R 6 and R 7 , or R 6a and R 7a together with the nitrogen to which thery are attached combine to form an optionally substituted saturated or unsaturated 5 to 8 membered ring;
  • R 4 , R 8 , R 8a1 , R 8c , R 9 , R 10 , R 10a , R 11 , R 11a , X, X 1 , Z 1 and W are as defined above.
  • More preferred compounds within the scope of formula I include compounds and salts thereof wherein one or more, and especially all of R 1 , R 1a , R 2a , J and R 3 are selected from the following definitions:
  • R 1 is hydrogen, hydroxy, —O—C(O)—NR 6 R 7 , —O—C(O)—R 4 , —N(R 8 )—SO 2 —NR 6 R 7 , —SO 2 R 8c , —N(R 8 )—C(W)—NR 6 R 7 , —N(R 8 )—C(Z)-N(R 8a )—SO 2 —R 4 , —N(R 8 )—C(Z)-N(R 8a )—SO 2 —OH, or a group
  • R 1a is H,
  • R 2 is phenyl, napthyl, thienyl benzothienyl, alkyl or alkenyl any of which may be optionally substituted as described above;
  • J is a bond, methylene or ethylene
  • R 3 is —R 5 , —C(Z 1 )-R 5 , —O—C(Z 1 )-R 5 , or —N(R 8a1 )—C(Z 1 )-R 5 ;
  • R 5 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroayl, optionally substituted aryl or —NR 6a R 7a ;
  • R 6 , R 6a , R 7 and R 7a are independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted (aryl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted (heterocylco)alkyl, optionally substituted alkyl, or COR 12 ;
  • R 6 and R 7 , or R 6a and R 7a together with the nitrogen to which thery are attached combine to form an optionally substituted saturated or unsaturated 5 to 8 membered ring;
  • R 4 , R 8 , R 8a1 , R 8c , R 9 , R 10 , R 10a , R 11 , R 11a , X, Z 1 and W are as defined above.
  • R 1 , R 1a , R 2 , J and R 3 are selected from the following definitions:
  • R 6 and R 7 are independently
  • R 6 and R 7 combine to form a heterocylo ring optionally substituted with one or more OH, SH, OT 6 , ST 6 , C(O) t T 6 , NT 7 T 8 , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH)alkyl, (SH)alkyl, (OT 6 )alkyl, (ST 6 )alkyl, (C(O) t T 6 )alkyl, (NT 7 T 8 )alkyl, (cyano)alkyl, (aryl)alkyl, (heteroaryl)alkyl or (heterocyclo)alkyl; and
  • R 4 is
  • R 8 and R 8a are independently
  • R 1a is H,
  • R 2 is phenyl, (phenyl)alkyl, napthyl, thienyl benzothienyl, alkyl or alkenyl any of which may be optionally independently substituted with one or more OH, SH, OT 6 , ST 6 , C(O) t T 6 , NT 7 T 8 , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH)alkyl, (SH)alkyl, (OT 6 )alkyl, (ST 6 )alkyl, (C(O) t T 6 )alkyl, (NT 7 T 8 )alkyl, (cyano)alkyl, (aryl)alkyl, (heteroaryl)alkyl or (heterocyclo)alkyl;
  • J is a bond, methylene or ethylene
  • R 3 is
  • R 5 is heteroaryl, heterocyclo or —NR 6a R 7a any of which may be optionally independently substituted with one or more OH, SH, OT 6 , ST 6 , C(O) t T 6 , NT 7 T 8 , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH)alkyl, (SH)alkyl, (OT 6 )alkyl, (ST 6 )alkyl, (C(O) t T 6 )alkyl, (NT 7 T 8 )alkyl, (cyano)alkyl, (aryl)alkyl, (heteroaryl)alkyl or (heterocyclo)alkyl;
  • R is aryl, (aryl)alkyl, heteroaryl, (heteroaryl)alkyl) or —NR 6a R 7a ;
  • R 6a and R 7a are independently
  • R 5 is aryl, (aryl)alkyl, hetreoaryl, (heteroaryl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl, alkynyl, cycloalkyl, (alkoxy)alkyl, or (cycloalkoxy)alkyl any of which may be optionally independently substituted with one or more OH, SH, OT 6 , ST 6 , C(O) t T 6 , NT 7 T 8 , cyano, halo, oxo, alkyl, haloalkyl, aryl, heteroaryl, heterocyclo, (OH)alkyl, (SH)alkyl, (OT 6 )alkyl, (ST 6 )alkyl, (C(O) t T 6 )alkyl, (NT 7 T 8 )alkyl, (cyano)alkyl, (aryl)alkyl, (heteroaryl
  • R 5 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroayl, optionally substituted aryl or —NR 6a R 7a ;
  • R 6 , R 6a , R 7 and R 7a are independently H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted (aryl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted (heterocylco)alkyl, optionally substituted alkyl, or COR 12 ;
  • R 6 and R 7 , or R 6a and R 7a together with the nitrogen to which thery are attached combine to form an optionally substituted saturated or unsaturated 5 to 8 membered ring;
  • R 4 , R 8 , R 8a1 , R 8c , R 9 , R 10 , R 10a , R 11 , R 11a , X, Z 1 and W are as defined above.
  • alk refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, etc.
  • Lower alkyl groups that is, alkyl groups of 1 to 6 carbon atoms, are generally most preferred.
  • substituted alkyl refers to alkyl groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • alkenyl refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 4 carbon atoms, and at least one double carbon to carbon bond (either cis or trans), such as ethenyl.
  • substituted alkenyl refers to alkenyl groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • alkynyl refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 4 carbon atoms, and at least one triple carbon to carbon bond, such as ethynyl.
  • substituted alkynyl refers to alkynyl groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T or —S(O) t N(T 9 )T 6 .
  • alkylene refers to a straight chain bridge of 1 to 4 carbon atoms connected by single bonds (e.g., —(CH 2 ) x — wherein x is 1 to 5), which may be substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • alkenylene refers to a straight chain bridge of 2 to 5 carbon atoms having one or two double bonds that is connected by single bonds and may be substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • alkenylene groups are —CH ⁇ CH—CH ⁇ CH—, —CH 2 —CH ⁇ CH—, —CH 2 —CH ⁇ CH—CH 2 —, —C(CH 3 ) 2 CH ⁇ CH— and —CH(C 2 H 5 )—CH ⁇ CH—.
  • alkynylene refers to a straight chain bridge of 2 to 5 carbon atoms that has a triple bond therein, is connected by single bonds, and may be substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , —T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • Exemplary alkynylene groups are —C ⁇ C—, —CH 2 —C ⁇ C—, —CH(CH 3 )—C ⁇ C— and —C ⁇ C—CH(C 2 H 5 )CH 2 —.
  • aromatic homocyclic i.e., hydrocarbon
  • bi- or tricyclic ring-containing groups preferably having 6 to 14 members such as phenyl, naphthyl and biphenyl, as well as such rings fused to a cycloalkyl, cycloalkenyl, heterocyclo, or heteroaryl ring. Examples include:
  • substituted aryl refers to aryl groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected cyano, halo, oxo, hydroxy, —OT 6 , C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • cycloalkyl refers to saturated and partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 7 carbons, forming the ring and which may be fused to 1 or 2 aromatic or heterocyclo rings, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl,
  • substituted cycloalkyl refers to cycloalkyl groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • halogen and “halo” refer to fluorine, chlorine, bromine and iodine.
  • heterocycle refers to fully saturated or partially or unsaturated cyclic groups (for example, 3 to 13 member monocyclic, 7 to 17 member bicyclic, or 10 to 20 member tricyclic ring systems, preferably containing a total of 3 to 10 ring atoms) which have at least one heteroatom in at least one carbon atom-containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be substituted or quaternized.
  • the heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system.
  • the rings of multi-ring heterocycles may be either fused, bridged and/or joined through one or more spiro unions.
  • Exemplary heterocyclic groups include
  • substituted heterocycle refers to heterocycle, heterocyclic and heterocyclo groups substituted with one or more groups listed in the definition of T 1-1g , T 2-2g and T 3-3g , preferably selected from cyano, halo, oxo, hydroxy, —OT 6 , —C(O) t T 6 , —OC(O)T 6 , -T 4 -NT 7 T 8 , -T 4 -N(T 9 )-T 5 -T 6 , —S(O) t T 6 or —S(O) t N(T 9 )T 6 .
  • heteroaryl refers to a 5-6- or 7-membered aromatic rings containing from 1 to 4 nitrogen atoms and/or 1 or 2 oxygen or sulfur atoms provided that the ring contains at least 1 carbon atom and no more than 4 heteroatoms.
  • the heteroaryl ring is linked through an available carbon or nitrogen atom.
  • such rings fused to a cycloalkyl, aryl, cycloheteroalkyl, or another heteroaryl ring.
  • One, two, or three available carbon or nitrogen atoms in the heteroaryl ring can be optionally substituted with substituents listed in the description of T 1 , T 2 and T 3 .
  • the compounds of formula I form salts which are also within the scope of this invention.
  • Reference to a compound of the formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term “salt(s)”, as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases.
  • zwitterions inner salts
  • Pharmaceutically acceptable salts are preferred, although other salts are also useful, e.g., in isolation or purification steps which may be employed during preparation.
  • Salts of the compounds of the formula I may be formed, for example, by reacting a compound I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • the compounds of formula I which contain a basic moiety may form salts with a variety of organic and inorganic acids.
  • Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates
  • the compounds of formula I which contain an acidic moiety may form salts with a variety of organic and inorganic bases.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • organic bases for example, organic amines
  • organic bases for example, organic amines
  • benzathines such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl
  • Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • the term “prodrug”, as employed herein, denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of the formula I, or a salt and/or solvate thereof.
  • Solvates of the compounds of formula I are preferably hydrates.
  • All stereoisomers of the present compounds such as those which may exist due to asymmetric carbons on the various R and Z substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons) and diastereomeric forms, are contemplated within the scope of this invention.
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • Compound 1 used in this preparation is readily prepared from commercially available reagents by the methods well known to those skilled in the art. Assembly of substituted cyclohexyl cyanoguanidines such as compound 3 can be done using methodology described in Scheme 2. Hydrolysis of the TFA protecting group and acylation of the amine 4 may provide the compounds of formula 5.
  • the amine 1 may be converted to the corresponding sulfonyl oxazolidine in a way described in the literature (Dewynter, G., et als. Tetrahedron, 1996, 52, 14217-14224).
  • Compounds of formula 3 may be prepared by displacement reaction of oxazolidine 2 with amines at temperature of 65-75° C. in alcholic solvents such as ethanol and isopropanol.
  • Treatment of the amine 1 with isothiocyanoformate may provide the thiourea 2, which would provide the compounds of formula 3 by the coupling with the amine in the presence of EDCI.
  • the isocyanate 2 could be obtained upon treating the amine 1 with phosgene. Treatment of the isocyanate 2 with substituted aminoester at 65-75° C. in alcoholic solvents such as ethanol or isopropanol can provide the compounds of formula 3.
  • compounds of formula 3 could be obtained by treating the amine 1 with substituted isocyanoactate in proper solvents such as dichloromethane or THF, followed by ring closure under acidic conditions according to Scheme 7.
  • Reductive amination of the ketone 1 with the substituted ethylenediamine 2 may provide cyclohexylamine 3.
  • the amine 3 can be converted to the corresponding cyclic ureas of formula 5 upon treatment with carbonyl diimidazole 4 in a solvent such as THF or dichloromethane.
  • the same intermediate 1 from Scheme 7 may produce the compounds of formula 3 upon treating it with diphenyl cyanocarbonidate 2 at temperature of 65-75° C. in alcholic solvents such as ethanol or isopropanol.
  • the intermediate 1 may react with a substituted aryl or heteroaryl compound where X is Cl, Br, I, OTf or similar leaving group in the presence of a palladium catalyst such as Pd 2 (dba) 3 to produce compound 2.
  • a palladium catalyst such as Pd 2 (dba) 3
  • the carboxylic acid 1 may be made to react with amine HNR 6 R 7 using a variety of standard coupling procedures known in the literature to give amide compounds of formula 2.
  • Activation of the carboxylic acid by conversion to the carboxylic acid chloride or carboxylic acid fluoride in a solvent such as methylene chloride or acetonitrile followed by reaction with an amine in the presence of a base such as triethylamine or pyridine is a particularly useful coupling procedure.
  • Nitrile 1 may be made to react with hydoxylamine in an organic solvent such as n-propanol to give carboxamidine 2.
  • Carboxamidine 2 may be acylated with a variety of carboxylic acids, carboxylic acid chlorides or carboxylic acid fluorides using standard coupling procedures and the resulting intermediates may be made to undergo cyclization upon heating to give 1,2,4-oxadiazole 3.
  • Deprotection of the ketal group of the 1,2,4-oxadiazole 3 followed by reduction of the ketone using a reducing agent such sodium borohydride in an organic solvent such as tetrahydrofuran gives hydroxy compound 4.
  • the hydroxy compound 4 may be converted to the carbamate 5 by first reacting the hydroxy derivative with 4-nitrophenyl chloroformate to obtain the carbonate intermediate which is then reacted with an amine to form the carbamate.
  • Nitrile 1 may be made to react with sodium azide in a organic solvent such as N,N-dimethylformamide at elevated temperatures to form the tetrazole 2.
  • the tetrazole 2 may be alkylated by treatment with an alkyl halide in the presence of a base such as potassium carbonate in an organic solvent such as aceteonitrile.
  • Deprotection of the ketal group of the alkylated tetrazole 3 followed by reduction of the ketone using a reducing agent such sodium borohydride in an organic solvent such as tetrahydrofuran gives the hydroxy compound 4.
  • the hydroxy compound 4 may be converted to the carbamate 5 by first reacting the hydroxy derivative with 4-nitrophenyl chloroformate to obtain the carbonate intermediate which is then reacted with an amine to form the carbamate.
  • the carboxylic acid 1 may react with an anthranilic acid using a variety of standard coupling procedures known in the literature to give amide compound 2. Cyclization of compound 2 under basic conditions in an organic solvent such as ethanol at elevated temperatures would give compounds of formula 3.
  • the carboxylic acid 1 may be made to react with a 2-aminophenol derivative using a variety of standard coupling procedures known in the literature to give amide compound 2. Cyclization of compound 2 under acidic conditions in an organic solvent such as p-xylene at elevated temperatures would give compounds of formula 3
  • the carboxylic acid 1 may be made to react with an o-phenylenediamine derivative using a variety of standard coupling procedures known in the literature to give amide compound 2. Cyclization of compound 2 under acidic conditions in a solvent such as acetic acid at elevated temperatures would give compounds of formula 3.
  • the nitrile 1 may be converted to the carboxylic acid 2 by treatment with a base such as sodium hydroxide in a solvent such as ethylene glycol at elevated temperatures.
  • the carboxylic acid 2 may be made to react with an amine HNR 6a R 7a using a variety of standard coupling procedures known in the literature to give amide compounds 3.
  • Deprotection of the ketal group of the amide 3 followed by reduction of the ketone using a reducing agent such as sodium borohydride in an organic solvent such as tetrahydrofuran gives the hydroxy compound 4.
  • the hydroxy compound 4 may be converted to the carbamate of formula 5 by first reacting the hydroxy derivative 4 with 4-nitrophenyl chloroformate to obtain the carbonate intermediate which is then reacted with HNR 6 R 7 to form the carbamate.
  • the carboxylic acid 1 may be made to react with an amine HNR 6a R 7a using a variety of standard coupling procedures known in the literature to give amide compounds 2.
  • Deprotection of the ketal group of the amide 2 followed by reductive amination of the ketone by first treating the ketone with amine H 2 NR 8 to form the imine intermediate followed by reduction of the imine with a reducing agent such as and sodium cyanoborohydride in an organic solvent such as methanol gives the amino compound 3.
  • the amino compound 3 may be made to react with a carboxylic acid R 4 CO 2 H using a variety of standard coupling procedures to give compound 4.
  • Amine 1 may react with diphenylcyanocarbonimidate in a solvent such as acetonitrile at elevated temperature to give an intermediate 2 which can further react with amine HNR 6 R 7 to give compound 3.
  • cardiac arrhythmias including supraventricular arrhythmias, atrial arrhythmias, atrial flutter, atrial fibrillation, complications of cardiac ischemia, and use as heart rate control agents; angina pectoris including relief of Prinzmetal's symptoms, vasospastic symptoms and variant symptoms; gastrointestinal disorders including reflux esauphagitis, functional dispepsia, motility disorders (including constipation and diarrhea), and irritable bowel syndrome; disorders of vascular and visceral smooth muscle including asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, peripheral vascular disease (including intermittent claudication), venous insufficiency, impotence, cerebral and coronary spasm and Raynaud's disease; inflammatory and immunological disease including inflammatory bowel disease, rheumatoid
  • inhibitors of the K v 1 subfamily of voltage-gated K + channels compounds of the present invention are useful to treat a variety of disorders including resistance by transplantation of organs or tissue, graft-versus-host diseases brought about by medulla ossium transplantation, rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes uveitis, juvenile-onset or recent-onset diabetes mellitus, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, infectious diseases caused by pathogenicmicroorganisms, inflammatory and hyperproliferative skin diseases, psoriasis, atopical dermatitis, contact dermatitis, eczematous dermatitises, seborrhoeis dermatitis, lichen planus, pemphigus, bullous pemphigoid, epi
  • the compounds of the present invention are antiarrhythmic agents which are useful in the prevention and treatment (including partial alleviation or cure) of arrhythmias.
  • As inhibitors of K v 1.5 compounds within the scope of the present invention are particularly useful in the selective prevention and treatment of supraventricular arrhythmias such as atrial fibrillation, and atrial flutter.
  • supraventricular arrhythmias By “selective prevention and treatment of supraventricular arrhythmias” is meant the prevention or treatment of supraventricular arrhythmias wherein the ratio of the prolongation of the atrial effective refractory period to the prolongation of the ventricular effective refractory period is greater than 1:1. This ratio is preferably greater than 4:1, more preferably greater than 10:1, and most preferably such that prolongation of the atrial effective refractory response period is achieved without significantly detectable prolongation of the ventricular effective refractory period.
  • I Kur -associated condition is a disorder which may be prevented, partially alleviated or cured by the administration of an I Kur blocker.
  • the Kv1.5 gene is known to be expressed in stomach tissue, intestinal/colon tissue, the pulmonary artery, and pancreatic beta cells.
  • administration of an I Kur blocker could provide useful treatment for disorders such as: reflux esauphagitis, functional dispepsia, constipation, asthma, and diabetes.
  • Kv1.5 is known to be expressed in the anterior pituitary.
  • administration of an I Kur blocker could stimulate growth hormone secretion.
  • I Kur inhibitors can additionally be useful in cell poliferative disorders such as leukemia, and autoimmune diseases such as rheumatoid arthritis and transplant rejection.
  • the present invention thus provides methods for the prevention or treatment of one or more of the aforementioned disorders, comprising the step of administering to a subject in need thereof an effective amount of at least one compound of the formula I.
  • Other therapeutic agents such as those described below may be employed with the inventive compounds in the present methods.
  • such other therapeutic agent(s) may be administered prior to, simultaneously with or following the administration of the compound(s) of the present invention.
  • the present invention also provides pharmaceutical compositions comprising at least one of the compounds of the formula I or salts thereof capable of preventing or treating one or more of the aforementioned disorders in an amount effective therefor, and a pharmaceutically acceptable vehicle or diluent.
  • the compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
  • the compounds of the formula I may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
  • suitable means for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; bucally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-a
  • the present compounds may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. In the case where the compounds of formula I are being administered to prevent or treat arrhythmias, the compounds may be administered to achieve chemical conversion to normal sinus rhythm, or may optionally be used in conjunction with electrical cardioconversion.
  • compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art.
  • the compounds of formula I may also be delivered through the oral cavity by sublingual and/or buccal administration.
  • Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used.
  • Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG).
  • Such formulations may also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g., Carbopol 934).
  • HPC hydroxy propyl cellulose
  • HPMC hydroxy propyl methyl cellulose
  • SCMC sodium carboxy methyl cellulose
  • maleic anhydride copolymer e.g., Gantrez
  • agents to control release such as polyacrylic copolymer (e.g., Carbopol 934).
  • Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.
  • compositions for nasal aerosol or inhalation administration include solutions in saline which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
  • compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • compositions for rectal administration include suppositories which may contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
  • a topical carrier such as Plastibase (mineral oil gelled with polyethylene).
  • the effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for an adult human of from about 0.001 to 100 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
  • Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats and the like, subject to the aforementioned disorders.
  • the compounds of the present invention may be employed alone or in combination with each other and/or other suitable therapeutic agents useful in the treatment of the aforementioned disorders or other disorders, including: other antiarrhythmic agents such as Class I agents (e.g., propafenone), Class II agents (e.g., carvadiol and propranolol), Class III agents (e.g., sotalol, dofetilide, amiodarone, azimilide and ibutilide), Class IV agents (e.g., diltiazem and verapamil), 5HT antagonists (e.g., sulamserod, serraline and tropsetron), and dronedarone; calcium channel blockers (both L-type and T-type) such as diltiazem, verapamil, nifedipine, amlodipine and mybefradil; Cyclooxygenase inibitors (i.e., COX-1 and/or COX-2 inhibitor
  • squalene synthetase inhibitors such as squalene synthetase inhibitors, fibrates, and bile acid sequestrants (e.g., questran); antipoliferative agents such as cyclosporin A, taxol, FK 506, and adriamycin; antitumor agents such as taxol, adriamycin, epothilones, cisplatin and carboplatin; anti-diabetic agents such as biguanides (e.g.
  • metformin metformin
  • glucosidase inhibitors e.g. acarbose
  • insulins meglitinides (e.g. repaglinide)
  • sulfonylureas e.g. glimepiride, glyburide and glipizide
  • biguanide/glyburide combinations i.e,. glucovance
  • thiozolidinediones e.g.
  • cilostazol e.g., sildenafil
  • protein tyrosine kinase inhibitors e.g., sildenafil
  • steroidal anti-inflammatory agents such as prednisone, and dexamethasone
  • other anti-inflammatory agents such as enbrel.
  • Assays to determine the degree of activity of a compound as an inhibitor of other members of the K v 1 subfamily are also well known in the art.
  • inhibition of K v 1.1, K v 1.2 and K v 1.3 can be measured using procedures described by Grissmer S, et al., Mol Pharmacol June 1994;45(6):1227-34.
  • Inhibition of Kv1.4 can be measured using procedures described by Petersen K R, and Nerbonne J M, Pflugers Arch February 1999;437(3):381-92.
  • Inhibition of Kv1.6 can be measured using procedures described by Bowlby M R, and Levitan I B, J Neurophysiol June 1995;73(6):2221-9.
  • inhibition of Kv1.7 can be measured using procedures described by Kalman K, et al., J Biol Chem Mar. 6, 1998;273(10):5851-7.
  • Compound 3 Compound 2 (1.10 g, 3.72 mmol) was dissolved in anhydrous dimethylethylene glycol (20 mL). Sodium hydride (60% dispersion in mineral oil, 360 mg, 11.2 mmol) was added slowly to the solution and the resulting brown slurry was heated under nitrogen to 95° C. for 4.5 h then allowed to cool overnight (12 h). The slurry was poured carefully into 15 mL of water and diluted with 100 mL ether. The organic portion was washed with HCl (3.7N, 2 ⁇ 20 mL), dried over anhydrous Na 2 SO 4 , decanted and concentrated yielding a brown oil.
  • HCl 3.N, 2 ⁇ 20 mL
  • Examples 2 to 12 were prepared using methodology described in Example 1. Ex. Structure Name [M + 1] 2 N-(4-Hydroxy-1- thiophen-3-yl- cyclohexylmethyl)-2- methoxy-benzamide 346 3 N-(4-Hydroxy-1- thiophen-3-yl- cyclohexylmethyl)-2- methoxy-benzamide 346 4 N-[1-(3-Ethyl-5- methyl-isoxazol-4- yl)-4-hydroxy- cyclohexylmethyl]-2- methoxy-benzamide 373 5 N-(1- Benzo[b]thiophen-3- yl-4-hydroxy- cyclohexylmethyl)-2- methoxy-benzamide 396 6 N-(1- Benzo[b]thiophen-3- yl-4-hydroxy- cyclohexylmethyl)-2- methoxy-benzamide 396 7 2,5-Dimethyl-furan
  • Compound 3 A solution of ethylamine (0.8 mL, 2.0M in THF) was added to a solution of 2 (32 mg, 0.062 mmol) in dichloromethane (3 mL) at ambient temperature. After 1 h the yellow solution was loaded directly onto a preparative thin layer chrmoatography plate (25 ⁇ 25 cm, 1 mm with UV indicator at 254 nm). The plate was eluted using 1:1 hexane:ethylacetate to provide 11 mg (43% yield) of 3 as a colorless glass.
  • Examples 14 to 27 were prepared using methodology described in Example 13. Ex. Structure Name [M + 1] 14 Ethyl-carbamic acid 4- [(2-methoxy- benzoylamino)- methyl]-4-thiophen-2- yl-cyclohexyl ester 417 15 Ethyl-carbamic acid 4- [(2-methoxy- benzoylamino)- methyl]-4-thiophen-2- yl-cyclohexyl ester 417 16 Ethyl-carbamic acid 4- [(2-methoxy- benzoylamino)- methyl]-4-thiophen-3- yl-cyclohexyl ester 417 17 Ethyl-carbamic acid 4- [(2-methoxy- benzoylamino)- methyl]-4-thiophen-3- yl-cyclohexyl ester 417 18 Ethyl-carbamic acid 4- (3-ethyl-5-methyl- isoxazol-4-yl
  • Examples 29 to 30 were synthesized using methodology described in Example 28. Ex. Structure Name [M + 1] 29 Butyric acid 4-[(2- methoxy- benzoylamino)- methyl]-4- thiophen-3- yl-cyclohexyl ester 416 30 Butyric acid 4-[(2- methoxy- benzoylamino)- methyl]-4- thiophen-3- yl-cyclohexyl ester 416
  • Compound 1 is commercially available.
  • Each of the amines were dissolved in 40 ml of 25% TFA/CH 2 Cl 2 and stirred at 25° C. for 2 h. They were concentrated in vacuo to provide oily residues, which were dissolved in EtOAc (150 ml, respectively) and washed with 1N aq. NaOH (100 ml ⁇ 2). The organic layers were dried over MgSO 4 and concentrated in vacuo to provide an oil, which corresponds to the amine of a single diastereoisomer.
  • Examples 32 to 52 were synthesized using methodology described in Example 31.
  • Ex. Structure Name (M + H) 32 cis-2-Methoxy-N- [4-(N-benzyl-N′- cyano-guanidino)-1- phenyl- cyclohexylmethyl]- benzamide 496 33 cis-2-Methoxy-N- [4-(N,N-diethyl- cyano-guanidino)-1- phenyl- cyclohexylmethyl]- benzamide 462
  • 34 cis-2-Methoxy-N- [4-(N,N-dipropyl- N′-cyano- guanidino)-1- phenyl- cyclohexylmethyl]- benzamide 490 35 cis-2-Methoxy-N- [4-(N-propyl-N′- cyano-guanidino)-1- phenyl- cyclohexylmethyl]- benzamide
  • Examples 54 to 61 were synthesized using methodology described in Example 53.
  • Ex. Structure Name (M + H) 54 trans-2-Methoxy-N-[4- (N-benzyl-N′- cyanoguanidino)-1- phenyl-cyclohexyl- methyl]-benzamide 434 55 trans-2-Methoxy-N-[4- (N,N-diethyl-N′- cyanoguanidino)-1- phenyl-cyclohexyl- methyl]-benzamide 490
  • the reaction was quenched by dropwise addition of 2N HCl and saturated with NaCl.
  • the organic layer was separated and the aqueous layer was extracted with dichloromethane (100 ml ⁇ 3).
  • the combined organic layer was dried over MgSO 4 and concentrated in vacuo to provide 2 as a white solid (2.0 g), which was subjected to the following reactions without further purification.
  • Examples 65 to 72 were synthesized using methodology described in Example 64.
  • Ex. Structure Name (M + H) 65 trans-2-Methoxy-N- [4-(N-methyl-N-benzyl- N′-sulfenylureido)- 1-phenyl-cyclohexyl- methyl]-benzamide 522 66 trans-2-Methoxy-N- [4-(N-tert-butyl-N′- sulfenylureido)-1- phenyl-cyclohexyl- methyl]-benzamide 474 67 trans-2-Methoxy-N- [4-(N-phenyl-N′- sulfenylureido)-1- phenyl-cyclohexyl- methyl]-benzamide 494 68 trans-2-Methoxy-N- [4-(N,N-diethyl-N′- sulfenylureido)-1- phenyl-cyclohex
  • Examples 74 to 147 were synthesized using methodology described in Example 73.
  • Examples 149 to 152 were synthesized using methodology described in Example 148.
  • Ex. Structure Name (M + H) 149 cis-N-[4-(N′,N′- dimethyl-guanidino)-1- phenyl-cyclohexyl- methyl]-2-methoxy-benzamide 409 150 cis-N-[4-(N′-benzyl- guanidino)-1-phenyl- cyclohexyl-methyl]-2- methoxy-benzamide 471 151 cis-N-[4-(N′-methyl- guanidino)-1-phenyl- cyclohexyl-methyl]-2- methoxy-benzamide 395 152 cis-N-[4-(N′-allyl- guanidino)-1-phenyl- cyclohexyl-methyl]-2- methoxy-benzamide 421
  • reaction mixture was concentrated to 2 ml of solution and purified on preparative HPLC (described in a synthesis of Example 31) to provide cis-isomer (retention time: 2.90 min) (70 mg) and trans-isomer (retention time: 2.65 min) (60 mg) of compound 5.
  • Examples 154 to 170 were synthesized using methodology described in Example 153.
  • Ex. Structure Name (M + H) 154 cis-2,4-Dimethoxy- N-[4-(N-methyl-N′- cyanoguanidino)-1- phenyl- cyclohexylmethyl]- benzamide 450 155 cis-2,4,5- Trimethoxy-N-[4-(N- methyl-N′- cyanoguanidino)-1- phenyl- cyclohexylmethyl]- benzamide 480 156 cis-2,3-Dimethoxy- N-[4-(N-methyl-N′- cyanoguanidino)-1- phenyl- cyclohexylmethyl]- benzamide 450 157 cis-2-Phenoxy-N-[4- (N-methyl-N′- cyanoguanidino)-1- phenyl- cyclohexylmethyl]- benzamide
  • Examples 172 to 178 were synthesized using methodology described in Example 171.
  • Ex. Structure Name (M + H) 172 2-Methoxy-N-[4-(N- ethyl-N′- ethoxycarbonyl- guanidino)-1-phenyl- cyclohexylmethyl]- benzamide 495 173 2-Methoxy-N-[4-(N- tert-butyl-N′- ethoxycarbonyl- guanidino)-1-phenyl- cyclohexylmethyl]- benzamide 509 174 2-Methoxy-N-[4-(N-n- hexyl-N′- ethoxycarbonyl- guanidino)-1-phenyl- cyclohexylmethyl]- benzamide 537 175 2-Methoxy-N-[4-(N,N- dipropyl-N′- ethoxycarbonyl- guanidino)-1-phenyl
  • Examples 184 to 192 were synthesized using methodology described in Example 183.
  • Ex. Structure Name (M + H) 184 cis-N-[4-(2,5-Dioxo-4- (s)-benzyl-imidazolin-1- yl)-1-phenyl- cyclohexylmethyl]-2- methoxy-benzamide 512 185 cis-N-[4-(2,5-Dioxo-4- (s)-isobutyl-imidazolin- 1-yl)-1-phenyl- cyclohexylmethyl]-2- methoxy-benzamide 478 186 cis-N-[4-(2,5-Dioxo-4- (s)-ethyl-imidazolin-1- yl)-1-phenyl- cyclohexylmethyl]-2- methoxy-benzamide 450 187 cis-N-[4-(2,5-Dioxo-4- (s)
  • the white solid (230 mg) was comprised of two diastereoisomers in a 1:1 ratio.
  • the mother liquor was concentrated in vacuo to provide an oil, which was purified on prep-HPLC (described in a synthesis of Example 31) to yield 16.1 mg of one isomer (retention time: 2.82 min).
  • the white solid was dissolved in 30 ml of hot EtOH and stored for 5 days at 25° C. to provide 55.7 mg a white solid precipitate of the other isomer.
  • Mass Spec for both compounds [M+H] + 408.
  • Compound 4 Compound 2 was dissolved in 20 ml of 3N aq. HCl and stirred for 12 h at 25° C. The reaction was cooled to 0° C., basified with 20% aq. NaOH and extracted with dichloromethane (50 ml ⁇ 3). The organic layer was dried over MgSO 4 and concentrated in vacuo to provide 157 mg of 4.
  • Compound 4 Compound 3 was dissolved in 20 ml of 3N aq. HCl and stirred for 12 h at 25° C. The reaction was cooled to 0° C, basified with 20% aq. NaOH and extracted with dichloromethane (50 ml ⁇ 3). The organic layer was dried over MgSO 4 and concentrated in vacuo to provide 135 mg of 4.
  • Compound 1 is commercially available.
  • Compound 1 is commercially available.
  • Examples 294 to 322 were synthesized using methodology described in Example 293. In some cases, further purification was accomplished using reverse phase HPLC.
  • Ex. Structure Name M + H 295 4-Phenyl-4-(5- phenyl- [1,2,4]oxadiazol-3- yl)-cyclohexanone 319.4 296 4-[5-(2-Methoxy- phenyl)- [1,2,4]oxadiazol-3- yl]-4-phenyl- cyclohexanone 349.4 297
  • Ethyl-carbamic acid 4-phenyl-4-(5- phenyl- [1,2,4]oxadiazol-3- yl)-cyclohexyl ester 392.5 298
  • Ethyl-carbamic acid 4-[5-(2-methoxy- phenyl)- [1,2,4]oxadiazol-3- yl]-4-phenyl- cyclohexyl ester 422.5 299 Ethyl
  • Compound 3 A mixture of compound 1 (2.0 g, 8.09 mmol), 2 (1.1 g, 6.75 mmol), sodium-t-butoxide (908 mg, 9.75 mmol), palladium acetate (75.7 mg, 0.34 mmol) and 2-(di-t-butylphosphino)biphenyl (100.7 mg, 0.3374 mmol) in toluene (20 mL) was heated at 110° C. for 20 h.
  • Examples 326 to 329 were synthesized using methodology described in Example 325.
  • Compound 1 is commercially available.
  • Compound 1 is commercially available.
  • Examples 333 to 334 were synthesized using methodology described in Example 332.
  • Compound 1 is commercially available.
  • Compound 2 is prepared in an exact same procedure as described in synthesis of Example 333 where 3-fluorophenylacetonitrile replaced 2-fluorophenylacetonitrile in synthesis of Example 335.
  • Examples 336 to 341 were synthesized using methodology described in Example 335.
  • Compound 1 is commercially available.
  • Compound 2 is prepared in an exact same procedure as described in synthesis of Example 332 where 4-fluorophenylacetonitrile replaced the 2-fluorophenylacetonitrile.
  • Examples 343 to 348 were synthesized using methodology described in Example 342.
  • Examples 350 to 396 were synthesized using methodology described in Example 349.
  • Exam- [M + ple Structure H] 350 567 351 567 352 567 353 620 354 509 355 548 356 524 357 566 358 496 359 537 360 537 361 485 362 523 363 527 364 529 365 537 366 495 367 529 368 515 369 539 370 595 371 531 372 581 373 523 374 523 375 418 376 539 377 567 378 538 379 632 380 607 381 646 382 600 383 647 384 588 385 588 386 588 387 608 388 608 389 574 390 574 391 609 392 653 393 618 394 628 395 590 396 579
  • Compound 1 is commercially available.
  • Compound 2 is prepared in an exact same procedure as described in synthesis of Example 332 where 2-methoxyphenylacetonitrile replaced the 2-fluorophenylacetonitrile in synthesis of Example 332.
  • Examples 398 to 404 were synthesized using methodology described in Example 397.
  • Examples 406 to 410 were synthesized using methodology described in Example 405. Exam- [M + ple Structure H] 406 596 407 596 408 538 409 538 410 539
  • Compound 2 To a specially designed vial for microwave reactor was added compound 1 (0.57 g, 2.3 mmol), Pd 2 (dba) 3 (42 mg, 0.046 mmol), BINAP (79 mg, 0.13 mmol) and t-BuONa (0.38 g, 2.3 mmol) in a portion. The reaction vial was placed under vacuum to remove air. Toward the mixture was, then, added 22 ml of degassed THF and the reaction vial was capped. The reaction mixture was placed in microwave reactor and heated for 20 min at 180° C. The reaction mixture was cooled down and placed on column chromatography (20-50% EtOAc/Hexane) to yield 0.62 g (72%) of the desired product as oily solid.
  • Examples 413 to 418 were synthesized using methodology described in Example 411.
  • Example Structure [M + H] 413 427 414 427 415 453 416 453 417 439 418 439
  • Compound 2 was prepared as a part of the library synthesis. The general procedure is following:
  • Examples 420 to 449 were synthesized using methodology described in Example 419.
  • Exam- [M + ple Structure H] 420 396 421 426 422 434 423 446 424 447 425 451 426 459 427 482 428 493 429 494 430 498 431 518 432 368 433 380 434 400 435 404 436 408 437 409 438 415 439 420 440 420 441 434 442 434 443 450 444 450 445 460 446 471 447 500 448 506 449 483
  • Compound 2 was prepared as a part of the library synthesis. The general procedure is following:
  • Examples 451 to 562 were synthesized using methodology described in Example 450.
  • the alcohol was dissolved in 30 ml of DCM and added pyridine (10 ml) and methanesulfonyl chloride (1.1 ml, 13.6 mmol) at 0° C. The resulting solution was stirred for 12 h at 25° C. The reaction was quenched by adding water. Aqueous layer was further extracted with DCM (20 mL ⁇ 2). The combined organic solution was washed with 1N aq. HCl (30 ml ⁇ 2) and dried over Na 2 SO 4 . Concentration of the organic solution provided the desired product (5.2 g, 85% pure) as an oil, which was subjected to following reaction without any further purification.
  • Compound 6 The compound 5 was dissolved in 30 ml of MeOH and was added catalytic amount of 10% Pd/C. The mixture was placed under H 2 and stirred for 2 h at 25° C. The reaction mixture was filtered through celite assisted funnel. The filtrate was concentrated in vacuo to provide the desired product (1.4 g, 75%) as a colorless oil.
  • Examples 564 to 571 were synthesized using methodology described in Example 563.
  • Examples 574 to 579 were synthesized using methodology described in Example 572.
  • Examples 581 to 590 were synthesized using methodology described in Example 580.
  • Examples 592 and 593 were synthesized using methodology described in Example 591.
  • Compound 1 is commercially available.
  • Reaction mixture was, then, diluted with EtOAc (250 mL) and washed with brine (50 ml ⁇ 3). Organic layer was dried over MgSO4 and concentrated in vacuo to provide oily residue, which was purified on CombiFlash (0 to 100% EtOAc/Hexane) to provide 5.6 g, (29 mmol, 73%) of the desired product as a mixture of cis and trans isomers (4:1).
  • Compound 5 Compound 4 was dissolved in 10 ml of DCM and 2 ml of pyridine. Toward the solution was added methanesulfonyl chloride (1 ml, 13 mmol) and the resulting solution was stirred for 2 h at 25° C. The reaction mixture was diluted with EtOAc (200 ml) and washed with brine (30 ml ⁇ 2). The organic layer was dried over MgSO 4 and concentrated in vacuo to provide an oil, which was subjected to following reaction without any further purification.
  • Examples 595 to 597 were synthesized using methodology described in Example 594.
  • Examples 600 to 604 were prepared using methodology described in Example 599.
  • Ex. Structure Name [M + 1] 600 Cis-N-[4-(N′-Cyano-N′′- ethyl-N-methyl-guanidino)- 1-phenyl-cyclohexylmethyl]- 2-methoxy-benzamide 448 601 Cis-N-[4-(N-Benzyl-N′- cyano-N′′-ethyl-guanidino)- 1-phenyl-cyclohexylmethyl]- 2-methoxy-benzamide 524 602 Cis-N-[4-(N′-Cyano-N′′- ethyl-N-pyridin-2-ylmethyl- guanidino)-1-phenyl- cyclohexylmethyl]-2-methoxy- benzamide 525 603 Cis-N-[4-(N′-Cyano-N′′- ethyl-N-pyridin-3-
  • Examples 606 to 609 were prepared using methodology described in Example 605. Ex. Structure Name [M + 1] 606 Trans-N-[4-(N′-Cyano-N′′- ethyl-N-methyl- guanidino)-1-phenyl- cyclohexylmethyl]-2- methoxy-benzamide 448 607 Trans-N-[4-(N′-Cyano-N′′- ethyl-N-pyridin-2- ylmethyl-guanidino)-1- phenyl-cyclohexylmethyl]- 2-methoxy-benzamide 525 608 Trans-N-[4-(N′-Cyano-N′′- ethyl-N-pyridin-3- ylmethyl-guanidino)-1- phenyl-cyclohexylmethyl]- 2-methoxy-benzamide 525 609 Trans-N-[4-(N′-Cyano-N′′- ethyl- eth
  • Examples 611 to 615 were prepared using methodology described in Example 610.
  • Ex. Structure Name [M + 1] 611 Cis-2-Methoxy-N- ⁇ 4- [methyl-(morpholine-4- sulfonyl)-amino]-1-phenyl- cyclohexylmethyl ⁇ - benzamide 502 612 Cis-N- ⁇ 4-[Benzyl- (morpholine-4-sulfonyl)- amino]-1-phenyl- cyclohexylmethyl ⁇ -2- methoxy-benzamide 578 613 Cis-2-Methoxy-N- ⁇ 4- [(morpholine-4-sulfonyl)- pyridin-2-ylmethyl- amino]-1-phenyl- cyclohexylmethyl ⁇ - benzamide 579 614 Cis-2-Methoxy-N- ⁇ 4- [(morpholine-4-sulfonyl)- pyridin-3-ylmethyl- amino]-1-phenyl- -
  • Examples 617 to 621 were prepared using methodology described in Example 616.
  • Ex. Structure Name [M + 1] 617 Trans-2-Methoxy-N- ⁇ 4- [methyl-(morpholine-4- sulfonyl)-amino]-1- phenyl- cyclohexylmethyl ⁇ - benzamide 502 618 Trans-N- ⁇ 4-[Benzyl- (morpholine-4- sulfonyl)-amino]-1- phenyl- cyclohexylmethyl ⁇ -2- methoxy-benzamide 578 619 Trans-2-Methoxy-N- ⁇ 4- [(morpholine-4- sulfonyl)-pyridin-2- ylmethyl-amino]-1- phenyl- cyclohexylmethyl ⁇ - benzamide 579 620 Trans-2-Methoxy-N- ⁇ 4- [(morpholine-4- sulfonyl)-pyridin-3- ylmethyl-amino
  • Compound 1 is commercially available.
  • Examples 623-647 may be prepared using methodology described in Example 622.
  • Ex. Structure Name [M + H] + 623 N-(1-Benzyl- cyclohexylmethyl)-2- trifluoromethyl-benzamide 376 624 N-(1-Benzyl- cyclohexylmethyl)-3- methoxy-benzamide 338 625 N-(1-Benzyl- cyclohexylmethyl)-3-cyano- benzamide 333 626 N-(1-Benzyl- cyclohexylmethyl)-2-fluoro- 6-trifluoromethyl- benzamide 394 627 N-(1-Benzyl- cyclohexylmethyl)-4-fluoro- 2-trifluoromethyl- benzamide 394 628 N-(1-Benzyl- cyclohexylmethyl)-2,4- difluoro- benzenesulfonamide 380 629 N-(1-Benzyl- cyclohexyl
  • Examples 650-660 were prepared using methodology described in Example 649. [M + Ex. Structure H] + 650 348 651 408 652 326 653 312 654 349 655 349 656 378 657 362 658 328 659 374 660 312
  • Compound 1 is commercially available.
  • Examples 663-665 were prepared using methodology described in Example 662.
  • Ex Structure Name [M + H] + 663 1-Isopropenyl- cyclohexanecarboxylic acid(3,3-diphenyl- propyl)-amide 362 664 1-Isopropenyl- cyclohexanecarboxylic acid(biphenyl-3- ylmethyl)-amide 334 665 1-Isopropenyl- cyclohexanecarboxylic acid isoquinolin-1- ylamide 295
  • Compound 1 may be prepared as described in Example 662.
  • Examples 667-668 were prepared using methodology described in Example 666. Ex Structure Name [M + H] + 667 1-Isopropyl- cyclohexanecarboxylic acid (3,3-diphenyl-propyl)- amide 364 668 1-Isopropyl- cyclohexanecarboxylic acid (biphenyl-3-ylmethyl)- amide 336
  • Compound 1 Compound I may be prepared as described in Example 662.
  • Example 670 was prepared using methodology described in Example 669: [M + Ex Structure Name H] + 670 N- Bicyclohexyl- 1′-en-1- ylmethyl-2- methoxy- benzamide 328
  • Compound 1 may be prepared as described in Example 330.
  • Compound 1 may be prepared as described in Example 330.
  • Compound 1 is commercially available.
  • Examples 675-680 were prepared using methodology described in Example 675.
  • Ex Structure Name [M + H] + 676 N-(4-Methyl-pyridin-2- yl)-3-phenyl-N-(1-phenyl- cyclohexylmethyl)- acrylamide 411 677 2-Methoxy-N-(4-methyl- pyridin-2-yl)-N-(1-phenyl- cyclohexylmethyl)- benzamide 415 678 N-(4-Methyl-pyridin-2- yl)-2-phenyl-N-(1-phenyl- cyclohexylmethyl)- acetamide 399 679 N-(4-Methyl-pyridin-2- yl)-N-(1-phenyl- cyclohexylmethyl)- benzamide 385 680 N-(4-Methyl-pyridin-2- yl)-N-(1-phenyl-
  • Compound 1 may be prepared as described in Example 330.
  • Compound 1 is commercially available.
  • Example 683 was prepared using methodology described in Example 682 [M + Ex structure Name H] + 683 2-Hydroxy-6- methoxy-N-[2- (1-phenyl- cyclohexyl)- ethyl]- benzamide 354
  • Examples 686-687 were prepared using methodology described in Example 685. [M + Ex structure Name H] + 686 1-Methyl-2-(1- phenyl- cyclohexylmethyl)- 1H-benzoimidazole 305 687 7-Methoxy-2-(1- phenyl- cyclohexylmethyl)- 1H-benzoimidazole 321
  • Compound 1 was prepared using methodology described in Example 682.
  • Examples 690-694 were prepared using methodology described in Example 325.
  • Ex structure Name [M + H] + 690 (1-Isopropenyl- cyclohexylmethyl)- isoquinolin-1-yl-amine 281 691 1-(3-Fluoro-phenyl)- cyclohexanecarboxylic acid isoquinolin-1- ylamide 349 692 1-(2-Fluoro-phenyl)- cyclohexanecarboxylic acid isoquinolin-1- ylamide 349 693 [1-(3-Fluoro-phenyl)- cyclohexylmethyl]- isoquinolin-1-yl-amine 335 694 [1-(2-Fluoro-phenyl)- cyclohexylmethyl]- isoquinolin-1-yl-amine 335

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US10/356,158 2002-02-01 2003-01-31 Cycloalkyl inhibitors of potassium channel function Abandoned US20040072880A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/356,158 US20040072880A1 (en) 2002-02-01 2003-01-31 Cycloalkyl inhibitors of potassium channel function
US10/997,734 US7202253B2 (en) 2002-02-01 2004-11-24 Cycloalkyl inhibitors of potassium channel function
US11/670,482 US20070142333A1 (en) 2002-02-01 2007-02-02 Cycloalkyl inhibitors of potassium channel function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35388402P 2002-02-01 2002-02-01
US10/356,158 US20040072880A1 (en) 2002-02-01 2003-01-31 Cycloalkyl inhibitors of potassium channel function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/997,734 Continuation US7202253B2 (en) 2002-02-01 2004-11-24 Cycloalkyl inhibitors of potassium channel function

Publications (1)

Publication Number Publication Date
US20040072880A1 true US20040072880A1 (en) 2004-04-15

Family

ID=27663264

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/356,158 Abandoned US20040072880A1 (en) 2002-02-01 2003-01-31 Cycloalkyl inhibitors of potassium channel function
US10/997,734 Expired - Lifetime US7202253B2 (en) 2002-02-01 2004-11-24 Cycloalkyl inhibitors of potassium channel function
US11/670,482 Abandoned US20070142333A1 (en) 2002-02-01 2007-02-02 Cycloalkyl inhibitors of potassium channel function

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/997,734 Expired - Lifetime US7202253B2 (en) 2002-02-01 2004-11-24 Cycloalkyl inhibitors of potassium channel function
US11/670,482 Abandoned US20070142333A1 (en) 2002-02-01 2007-02-02 Cycloalkyl inhibitors of potassium channel function

Country Status (23)

Country Link
US (3) US20040072880A1 (no)
EP (2) EP2253328A1 (no)
JP (2) JP4598397B2 (no)
KR (1) KR20040096542A (no)
CN (2) CN101704810A (no)
AR (1) AR038466A1 (no)
AU (2) AU2003210817B9 (no)
BR (1) BR0307329A (no)
CA (1) CA2474451A1 (no)
CO (1) CO5601004A2 (no)
GE (1) GEP20063923B (no)
HR (1) HRP20040667A2 (no)
IS (1) IS7370A (no)
MX (1) MXPA04007365A (no)
NO (1) NO329356B1 (no)
NZ (1) NZ534098A (no)
PL (1) PL375359A1 (no)
RU (1) RU2343143C2 (no)
TW (1) TW200307539A (no)
UA (1) UA87434C2 (no)
WO (1) WO2003063797A2 (no)
YU (1) YU66204A (no)
ZA (1) ZA200405905B (no)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096922A1 (en) * 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
US20100190861A1 (en) * 2006-01-06 2010-07-29 Liming Shao Cycloalkylamines as monoamine reuptake inhibitors
US20130123225A1 (en) * 2010-07-06 2013-05-16 North Carolina State University Inhibition of bacterial biofilms with aryl carbamates
US20130190361A1 (en) * 2010-09-24 2013-07-25 Bristol-Myers Squibb Company Substituted oxadiazole compounds
US9125408B2 (en) 2010-09-01 2015-09-08 North Carolina State University Use of aryl carbamates in agriculture and other plant-related areas
US9249155B2 (en) 2011-04-01 2016-02-02 Xention Limited Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia
US11660275B2 (en) 2018-03-20 2023-05-30 Eisai R&D Management Co., Ltd. Epilepsy treatment agent

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1886393A (zh) * 2003-10-08 2006-12-27 沃泰克斯药物股份有限公司 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
US7488747B2 (en) 2003-12-29 2009-02-10 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
KR101083506B1 (ko) 2005-07-15 2011-11-16 에프. 호프만-라 로슈 아게 신규한 헤테로아릴 융합된 환형 아민
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
JP2009515925A (ja) 2005-11-16 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー 凝固第Ｘａ因子のインヒビターとしての新規なピロリジン誘導体
GB0523998D0 (en) * 2005-11-25 2006-01-04 Merck Sharp & Dohme Therapeutic agents
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CN101426372A (zh) 2006-01-06 2009-05-06 塞普拉柯公司 基于四氢萘酮的单胺再摄取抑制剂
EP1984347A1 (en) 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
RU2008129797A (ru) 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
CA2648121C (en) 2006-03-31 2013-08-06 Sepracor Inc. Preparation of chiral amides and amines
AU2007236115A1 (en) 2006-04-11 2007-10-18 Novartis Ag Organic compounds
DE102006049527A1 (de) * 2006-10-20 2008-04-24 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und TASK-3 Ionenkanals
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
NZ572231A (en) * 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP2124913A1 (en) * 2006-12-22 2009-12-02 Novartis AG 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
CN101686672A (zh) 2007-05-31 2010-03-31 塞普拉柯公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
TW200922558A (en) 2007-09-28 2009-06-01 Mitsubishi Tanabe Pharma Corp Indazole acrylic and amide compound
CA2705562C (en) * 2007-11-16 2016-05-17 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
AU2008335440B2 (en) 2007-12-07 2013-11-07 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8299099B2 (en) 2008-02-28 2012-10-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
ES2875944T3 (es) 2008-03-18 2021-11-11 Arena Pharm Inc Moduladores del receptor de prostaciclina (PG12) útiles para el tratamiento de trastornos relacionados con el mismo
ES2552990T3 (es) * 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
AU2013270464B2 (en) * 2008-03-31 2016-05-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EA022799B1 (ru) * 2008-11-26 2016-03-31 Арена Фармасьютикалз, Инк. Пиразолилзамещенные производные угольной кислоты в качестве модуляторов рецептора простациклина (pgi2), применимые для лечения связанных с ним нарушений
PL2370413T3 (pl) 2008-12-08 2016-01-29 Arena Pharm Inc Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych
JPWO2010087150A1 (ja) * 2009-01-27 2012-08-02 静岡県公立大学法人 胃酸分泌抑制剤及びカリウムチャンネル阻害剤
US20120016117A1 (en) * 2009-03-27 2012-01-19 Tetsuo Yamaguchi Indazolepropionic acid amide compound
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
BR112012015868A2 (pt) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
KR102129247B1 (ko) * 2011-03-23 2020-07-06 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
NO3175985T3 (no) 2011-07-01 2018-04-28
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
HUE033583T2 (hu) * 2012-06-21 2017-12-28 Eisai R&D Man Co Ltd Új indánszulfamid származékok
FR2998892B1 (fr) * 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
TW201427945A (zh) * 2012-12-18 2014-07-16 Actelion Pharmaceuticals Ltd 作爲ｐ２ｘ７受體拮抗劑之吲哚羧醯胺衍生物
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
EP3461811A1 (en) 2013-06-17 2019-04-03 3M Innovative Properties Co. Process for preparing guanidino-functional monomers
US9738642B2 (en) 2013-09-19 2017-08-22 Bristol-Myers Squibb Company Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CN107106532A (zh) 2014-10-23 2017-08-29 艾尼纳制药公司 治疗与pgi2受体相关的病症的方法
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
CN106170304A (zh) * 2015-03-23 2016-11-30 北京大学深圳研究生院 生物正交试剂、活化剂和前体及生物正交试剂盒
CN105175278B (zh) * 2015-09-17 2017-06-23 上海大学 7‑肟醚酰胺脱氢枞酸化合物及其合成方法
WO2017106306A1 (en) 2015-12-14 2017-06-22 Trevena, Inc. Methods of treating hyperalgesia
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
WO2023203185A1 (en) * 2022-04-22 2023-10-26 Univerza V Ljubljani Mitochondriotropic benzamide potassium channel k v1.3 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281625A (en) * 1989-07-06 1994-01-25 Basf Aktiengesellschaft Fungicidal guanidines
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5631282A (en) * 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5679705A (en) * 1995-10-31 1997-10-21 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5696156A (en) * 1995-10-31 1997-12-09 Merck & Co. Inc. Triterpene derivatives with immunosuppressant activity
US6043265A (en) * 1997-01-30 2000-03-28 Bristol-Myers Squibb Co. Isoxazolyl endothelin antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1031088A (en) * 1964-04-16 1966-05-25 Hoechst Ag Benzenesulphonyl-ureas and process for their manufacture
JPS5843919A (ja) * 1981-08-04 1983-03-14 Hisamitsu Pharmaceut Co Inc 抗血栓剤
EP0125204A1 (de) 1983-04-12 1984-11-14 Ciba-Geigy Ag 3-Phenoxybenzyl-(2-phenyl-2,2-alkylen-äthyl)-äther und -thioäther, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
DE3814505A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Substituierte cycloalkyl- bzw. heterocyclyl-carbonsaeureanilide
JPH08504435A (ja) * 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
US5900415A (en) * 1994-11-07 1999-05-04 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
IL117997A0 (en) * 1995-06-07 1996-10-31 Pfizer Neuropeptide Y1 specific ligands
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
ES2214728T3 (es) * 1997-08-22 2004-09-16 F. Hoffmann-La Roche Ag Derivados de n-aroilfenilalanina.
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6194458B1 (en) * 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6632836B1 (en) * 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
GB0012214D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6660742B2 (en) * 2000-09-19 2003-12-09 Taiho Pharmaceutical Co. Ltd. Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins
GB0114867D0 (en) * 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281625A (en) * 1989-07-06 1994-01-25 Basf Aktiengesellschaft Fungicidal guanidines
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5631282A (en) * 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
US5679705A (en) * 1995-10-31 1997-10-21 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5696156A (en) * 1995-10-31 1997-12-09 Merck & Co. Inc. Triterpene derivatives with immunosuppressant activity
US6043265A (en) * 1997-01-30 2000-03-28 Bristol-Myers Squibb Co. Isoxazolyl endothelin antagonists

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
US20080096922A1 (en) * 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
US20100190861A1 (en) * 2006-01-06 2010-07-29 Liming Shao Cycloalkylamines as monoamine reuptake inhibitors
US10562878B2 (en) 2006-01-06 2020-02-18 Sunovion Pharamceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US9868718B2 (en) 2006-01-06 2018-01-16 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8877975B2 (en) 2006-01-06 2014-11-04 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8884022B2 (en) * 2010-07-06 2014-11-11 North Carolina State University Inhibition of bacterial biofilms with aryl carbamates
US20130123225A1 (en) * 2010-07-06 2013-05-16 North Carolina State University Inhibition of bacterial biofilms with aryl carbamates
US9125408B2 (en) 2010-09-01 2015-09-08 North Carolina State University Use of aryl carbamates in agriculture and other plant-related areas
US9439436B2 (en) 2010-09-01 2016-09-13 North Carolina State University Use of aryl carbamates in agriculture and other plant-related areas
US9918473B2 (en) 2010-09-01 2018-03-20 North Carolian State University Use of aryl carbamates in agriculture and other plant-related areas
US9187437B2 (en) * 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
US20130190361A1 (en) * 2010-09-24 2013-07-25 Bristol-Myers Squibb Company Substituted oxadiazole compounds
US9249155B2 (en) 2011-04-01 2016-02-02 Xention Limited Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia
US11660275B2 (en) 2018-03-20 2023-05-30 Eisai R&D Management Co., Ltd. Epilepsy treatment agent

Also Published As

Publication number Publication date
HRP20040667A2 (en) 2005-08-31
AU2003210817B9 (en) 2009-10-29
EP2253328A1 (en) 2010-11-24
JP2010180208A (ja) 2010-08-19
JP4598397B2 (ja) 2010-12-15
GEP20063923B (en) 2006-09-11
EP1507504A4 (en) 2006-07-05
AU2003210817B2 (en) 2009-07-16
ZA200405905B (en) 2006-05-31
KR20040096542A (ko) 2004-11-16
RU2004126608A (ru) 2005-05-10
CN100558697C (zh) 2009-11-11
NO20043645L (no) 2004-08-31
CA2474451A1 (en) 2003-08-07
NZ534098A (en) 2007-04-27
TW200307539A (en) 2003-12-16
JP5148646B2 (ja) 2013-02-20
YU66204A (sh) 2006-08-17
AU2009222566A1 (en) 2009-10-22
WO2003063797A8 (en) 2004-12-16
UA87434C2 (ru) 2009-07-27
AR038466A1 (es) 2005-01-19
EP1507504A1 (en) 2005-02-23
CN101704810A (zh) 2010-05-12
CO5601004A2 (es) 2006-01-31
PL375359A1 (en) 2005-11-28
MXPA04007365A (es) 2005-03-31
JP2006508016A (ja) 2006-03-09
RU2343143C2 (ru) 2009-01-10
IS7370A (is) 2004-07-23
BR0307329A (pt) 2006-04-11
US20070142333A1 (en) 2007-06-21
WO2003063797A2 (en) 2003-08-07
CN1732146A (zh) 2006-02-08
US7202253B2 (en) 2007-04-10
NO329356B1 (no) 2010-10-04
US20050234106A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
US7202253B2 (en) Cycloalkyl inhibitors of potassium channel function
AU2003210817A1 (en) Cycloalkyl inhibitors of potassium channel function
US7005436B2 (en) Heterocyclo inhibitors of potassium channel function
US8357704B2 (en) Fused heterocyclic compounds as inhibitors of potassium channel function
US9242966B2 (en) Phthalazines as potassium ion channel inhibitors
US9458133B2 (en) Isoquinolines as potassium ion channel inhibitors
EP1841741B1 (en) Piperidine derivatives as prodrugs of potassium channel inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: ICAGEN, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEAUDOIN, SERGE;GROSS, MICHAEL F.;REEL/FRAME:013488/0498

Effective date: 20030127

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LLOYD, JOHN;JEON, YOON T.;FINLAY, HEATHER;AND OTHERS;REEL/FRAME:013490/0329;SIGNING DATES FROM 20030127 TO 20030130

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION